Corvus Pharmaceuticals (CRVS) Income from Continuing Operations (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Income from Continuing Operations of 13093000.0 for Q1 2026, down 183.23% year-over-year from 15732000.0 in Q1 2025, and down 33.14% quarter-over-quarter from 9834000.0 in Q3 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 13093000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 183.23% year-over-year to 13093000.0; the TTM figure through Mar 2026 stood at 14804000.0 (up 55.71% YoY), while the FY2025 annual figure was 102099000.0, down 12.78% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 13093000.0, down from 9834000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 15732000.0 in Q1 2025, with the low at 39535000.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 6142000.0 (2023), against an average of 7988600.0.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 669.91% in 2024, then jumped 364.98% in 2025.
- Corvus Pharmaceuticals' Income from Continuing Operations stood at 5778000.0 in 2022, then gained by 0.8% to 5732000.0 in 2023, then plunged by 589.72% to 39535000.0 in 2024, then surged by 75.13% to 9834000.0 in 2025, then plunged by 33.14% to 13093000.0 in 2026.
- Business Quant data shows CRVS's Income from Continuing Operations at 13093000.0 in Q1 2026, 9834000.0 in Q3 2025, and 7609000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | -17.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.25 Mn |
| Mar 31, 2026 | -13.09 Mn |
| Sep 30, 2025 | -9.83 Mn |
| Jun 30, 2025 | -7.61 Mn |
| Mar 31, 2025 | 15.73 Mn |
| Sep 30, 2024 | -39.54 Mn |
| Jun 30, 2024 | -3.69 Mn |
| Mar 31, 2024 | -5.94 Mn |
| Dec 31, 2023 | -5.27 Mn |
| Sep 30, 2023 | -5.14 Mn |
| Jun 30, 2023 | -5.22 Mn |
| Mar 31, 2023 | -6.14 Mn |
| Dec 31, 2022 | -5.35 Mn |
| Sep 30, 2022 | -12.25 Mn |
| Jun 30, 2022 | -6.91 Mn |
| Mar 31, 2022 | -7.40 Mn |
| Dec 31, 2021 | -6.82 Mn |
| Sep 30, 2021 | -9.06 Mn |
| Jun 30, 2021 | -11.29 Mn |
| Mar 31, 2021 | -11.48 Mn |